Deakin University
Browse

File(s) under permanent embargo

The need to examine metastatic tissue at the time of progression of breast cancer : is re-biopsy a necessity or a luxury?

journal contribution
posted on 2011-02-01, 00:00 authored by Mustafa Khasraw, E Brogi, A Seidman
Knowledge of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor-2 (HER2) status is necessary for determining the optimal treatment of breast cancer patients. At the same time, the discordance between marker profiles (ER/PR and HER2) of primary and metastatic breast cancer is well documented. Whether discordant cases are secondary to “clonal selection” in the face of targeted anti-estrogen or anti-HER2 therapy or whether they are a laboratory artifact is still debated; both scenarios are likely. This article outlines current modalities for ER, PR, and HER2 testing in primary breast carcinoma and its metastases and reviews prospective and retrospective studies that have addressed these issues, as well as recent advances in the field.

History

Journal

Current oncology reports

Volume

13

Issue

1

Pagination

17 - 25

Publisher

Springer

Location

[Philadelphia, Pa.]

ISSN

1523-3790

eISSN

1534-6269

Language

eng

Publication classification

C3.1 Non-refereed articles in a professional journal

Copyright notice

2010, Springer Science+Business Media, LLC